C-type natriuretic peptide (CNP): The cardiovascular system and beyond.
C-type natriuretic peptide
Central nervous system
Cyclic GMP
G-protein coupled receptor
Heart
Kidney
Metabolism
Natriuretic peptide receptor
Vasculature
Journal
Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840
Informations de publication
Date de publication:
16 Aug 2024
16 Aug 2024
Historique:
received:
28
03
2024
revised:
30
07
2024
accepted:
15
08
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
18
8
2024
Statut:
aheadofprint
Résumé
C-type natriuretic peptide (CNP) represents the 'local' member of the natriuretic peptide family, functioning in an autocrine or paracrine capacity to modulate a hugely diverse portfolio of physiological processes. Whilst the best-characterised of these regulatory roles are in the cardiovascular system, akin to its predominantly endocrine siblings atrial (ANP) and brain (BNP) natriuretic peptides, CNP governs many additional, unrelated mechanisms including bone growth, gamete maturation, auditory processing, and neuronal integrity. Furthermore, there is currently great interest in mimicking the biological activity of CNP for therapeutic gain in many of these disparate organ systems. Herein, we provide an overview of the physiology, pathophysiology and pharmacology of CNP in both cardiovascular and non-cardiovascular settings.
Identifiants
pubmed: 39154787
pii: S0163-7258(24)00128-1
doi: 10.1016/j.pharmthera.2024.108708
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
108708Informations de copyright
Copyright © 2024. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing interest A.H. is a scientific advisory board member/consultant for Palatin Technologies Inc., Pharmain Corp. and Novo Nordisk. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Adrian Hobbs reports financial support was provided by British Heart Foundation. Yasmin Dickinson reports financial support was provided by Biotechnology and Biological Sciences Research Council. Adrian Hobbs reports a relationship with Novo Nordisk that includes: consulting or advisory and travel reimbursement. Adrian Hobbs reports a relationship with PharmaIN Corp that includes: consulting or advisory. Adrian Hobbs reports a relationship with Palatin Technologies Inc. that includes: consulting or advisory and funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.